[go: up one dir, main page]

DK3175863T3 - Varianter af c-type natriuretisk peptid - Google Patents

Varianter af c-type natriuretisk peptid Download PDF

Info

Publication number
DK3175863T3
DK3175863T3 DK16192229.9T DK16192229T DK3175863T3 DK 3175863 T3 DK3175863 T3 DK 3175863T3 DK 16192229 T DK16192229 T DK 16192229T DK 3175863 T3 DK3175863 T3 DK 3175863T3
Authority
DK
Denmark
Prior art keywords
peptime
natriurethic
variants
type
type natriurethic
Prior art date
Application number
DK16192229.9T
Other languages
English (en)
Inventor
Daniel J Wendt
Mika Aoyagi-Scharber
Shinong Long
Michel Claude Vellard
Sianna Castillo
Augustus O Okhamafe
Christopher P Price
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43124672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3175863(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Application granted granted Critical
Publication of DK3175863T3 publication Critical patent/DK3175863T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16192229.9T 2009-05-20 2010-05-20 Varianter af c-type natriuretisk peptid DK3175863T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18011209P 2009-05-20 2009-05-20
US25456309P 2009-10-23 2009-10-23
EP10778389.6A EP2432489B1 (en) 2009-05-20 2010-05-20 Variants of c-type natriuretic peptide

Publications (1)

Publication Number Publication Date
DK3175863T3 true DK3175863T3 (da) 2022-02-07

Family

ID=43124672

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10778389.6T DK2432489T3 (da) 2009-05-20 2010-05-20 Varianter af c-type natriuretisk peptid
DK16192229.9T DK3175863T3 (da) 2009-05-20 2010-05-20 Varianter af c-type natriuretisk peptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10778389.6T DK2432489T3 (da) 2009-05-20 2010-05-20 Varianter af c-type natriuretisk peptid

Country Status (28)

Country Link
US (6) US8198242B2 (da)
EP (4) EP4523749A2 (da)
JP (1) JP5718909B2 (da)
KR (5) KR101831923B1 (da)
CN (1) CN102481330B (da)
AR (1) AR078044A1 (da)
AU (1) AU2010249802B2 (da)
BR (2) BRPI1012783B1 (da)
CA (1) CA2758581C (da)
CL (1) CL2011002430A1 (da)
DK (2) DK2432489T3 (da)
ES (2) ES2904360T3 (da)
FI (1) FIC20220003I1 (da)
FR (1) FR22C1004I2 (da)
HK (1) HK1168279A1 (da)
HR (2) HRP20220057T1 (da)
HU (3) HUE057174T2 (da)
IL (1) IL215287A (da)
LU (1) LUC00248I2 (da)
MX (1) MX2011012277A (da)
NO (1) NO2022003I1 (da)
PE (1) PE20120792A1 (da)
PL (2) PL2432489T3 (da)
PT (2) PT2432489T (da)
RU (1) RU2573911C2 (da)
TW (1) TWI471137B (da)
WO (1) WO2010135541A2 (da)
ZA (1) ZA201107087B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2348114T3 (da) 2004-04-21 2018-09-03 Alexion Pharma Inc Knogleafgivelseskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
DK2432489T3 (da) 2009-05-20 2017-01-16 Biomarin Pharm Inc Varianter af c-type natriuretisk peptid
US20120208756A1 (en) * 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
CA2771215C (en) 2009-08-27 2013-01-22 Kyoko Endo Therapeutic preparation for rhinitis
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
AU2012287226A1 (en) * 2011-07-27 2014-02-20 Capricor Therapeutics, Inc. Natriuretic peptide compositions and methods of preparation
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013095759A1 (en) 2011-12-23 2013-06-27 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
KR20150013455A (ko) * 2012-04-25 2015-02-05 다이이찌 산쿄 가부시키가이샤 골 수복 촉진제
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104870020A (zh) * 2012-10-19 2015-08-26 康奈尔大学 用于关节软骨的仿生型界面润滑剂
KR20150124941A (ko) * 2013-03-10 2015-11-06 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 골 계통 질환 치료약 및 그 용도
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
US10323083B2 (en) 2014-01-15 2019-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that specifically bind matrilin-3 and their use
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
IL278970B2 (en) * 2015-01-09 2024-03-01 Ascendis Pharma Growth Disorders As Cnp prodrugs
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP4406599A3 (en) 2015-07-30 2024-11-06 BioMarin Pharmaceutical Inc. Use of c-type natriuretic peptide variants to treat skeletal dysplasia
EP3330280A4 (en) * 2015-07-31 2019-06-12 Igisu Co., Ltd. CYCLIC PEPTIDE CNP AND MEDICINE, PREPARATION FOR EXTERNAL USE AND COSMETIC PRODUCT, CONTAINING ALL OF SAID CYCLIC PEPTIDE
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP4019038A3 (en) * 2015-12-08 2022-09-28 BioMarin Pharmaceutical Inc. Use of c-type natriuretic peptide variants to treat osteoarthritis
IL259659B (en) * 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
RS63793B1 (sr) * 2016-01-08 2022-12-30 Ascendis Pharma Growth Disorders As Cnp prolekovi kod kojih je nosač povezan sa cikličnom komponentom
CN108472383B (zh) * 2016-01-08 2022-07-01 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
AU2017205693B2 (en) * 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
JP7051686B2 (ja) * 2016-01-08 2022-04-11 アセンディス ファーマ グロース ディスオーダーズ エー／エス 大型のキャリアー部分を有するｃｎｐプロドラッグ
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11896671B2 (en) * 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
SI3518930T1 (sl) * 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders A/S Kombinirana terapija z agonisti CNP s kontroliranim sproščanjem
US20180194824A1 (en) * 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
JPWO2018139464A1 (ja) * 2017-01-24 2019-11-07 第一三共株式会社 低身長症治療剤
DK3592393T3 (da) 2017-03-10 2022-03-07 Quiapeg Pharmaceuticals Ab Frigørbare konjugater
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
TWI834720B (zh) 2018-09-12 2024-03-11 瑞典商奎亞培格製藥公司 可釋放glp-1共軛物
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
MA56180A (fr) 2019-06-12 2022-04-20 Novartis Ag Anticorps du récepteur 1 du peptide natriurétique et procédés d'utilisation
CN114423447A (zh) * 2019-08-12 2022-04-29 生物马林药物股份有限公司 用于延释组合物的疏水性肽盐
MX2022003184A (es) 2019-09-16 2022-06-23 Biomarin Pharm Inc Variantes del cnp y sus conjugados.
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
US20240041982A1 (en) * 2020-11-25 2024-02-08 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
WO2022173987A1 (en) 2021-02-12 2022-08-18 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
RU2763661C2 (ru) * 2021-03-31 2021-12-30 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ терапии и профилактики прогрессирования хронической почечной недостаточности
JP2024525562A (ja) 2021-07-09 2024-07-12 バイオマリン ファーマシューティカル インコーポレイテッド 小児における骨格異形成症を治療するためのｃ型ナトリウム利尿ペプチドバリアント
TW202334188A (zh) * 2021-12-07 2023-09-01 美商拜奧馬林製藥公司 Ｃｎｐ療法
AU2022413318A1 (en) * 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
CN119256089A (zh) * 2022-03-11 2025-01-03 阿维麦克思生物制药公司 用于表达治疗剂的组合物和方法
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
TW202419463A (zh) 2022-11-02 2024-05-16 丹麥商諾佛 儂迪克股份有限公司 Cnp化合物
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024128729A1 (ko) * 2022-12-12 2024-06-20 주식회사 엘지생활건강 피부 개선용 화장료 조성물
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2024254405A2 (en) 2023-06-07 2024-12-12 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0478797B1 (en) 1990-04-20 1995-04-12 Hisayuki Matsuo Novel physiologically active peptide originating in hog
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6136040A (en) 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
IL125958A0 (en) 1998-08-27 1999-04-11 Yeda Res & Dev Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (en) 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
ATE421535T1 (de) 2000-10-16 2009-02-15 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20040077537A1 (en) * 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
PL377813A1 (pl) 2002-11-26 2006-02-20 Biocon Limited Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7919255B2 (en) * 2003-06-17 2011-04-05 Otago Innovation Limited Assessment of skeletal growth using measurements of NT-CNP peptides
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE602005026014D1 (de) * 2004-07-15 2011-03-03 Univ Queensland Proteinartige verbindungen und anwendungen davon
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP2162464A1 (en) 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
ES2472791T3 (es) * 2007-07-20 2014-07-03 Mayo Foundation For Medical Education And Research Polip�ptidos natriur�ticos
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086166A1 (en) 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
BRPI0906643A2 (pt) 2008-02-01 2019-09-10 Ascendis Pharma As profármaco compreendendo um conjugado fármaco-ligante
DK2277890T3 (da) * 2008-05-23 2016-02-08 Daiichi Sankyo Co Ltd Peptid, som er i stand til at forlænge halveringstiden for et peptid af interesse i plasma
US8449872B2 (en) 2008-09-19 2013-05-28 Nektar Therapeutics Polymer conjugates of nesiritide peptides
DK2432489T3 (da) * 2009-05-20 2017-01-16 Biomarin Pharm Inc Varianter af c-type natriuretisk peptid
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs

Also Published As

Publication number Publication date
HK1168279A1 (zh) 2012-12-28
ZA201107087B (en) 2012-12-27
DK2432489T3 (da) 2017-01-16
CL2011002430A1 (es) 2012-02-17
ES2904360T3 (es) 2022-04-04
HRP20220057T1 (hr) 2022-04-15
JP2012527244A (ja) 2012-11-08
WO2010135541A2 (en) 2010-11-25
EP3175863B1 (en) 2021-12-01
BR122019026832B1 (pt) 2021-08-24
TWI471137B (zh) 2015-02-01
TW201100092A (en) 2011-01-01
AR078044A1 (es) 2011-10-12
KR102225470B1 (ko) 2021-03-10
KR20180021233A (ko) 2018-02-28
KR20230142644A (ko) 2023-10-11
KR20190119179A (ko) 2019-10-21
KR20120034660A (ko) 2012-04-12
FR22C1004I1 (fr) 2022-03-11
IL215287A0 (en) 2011-11-30
US8198242B2 (en) 2012-06-12
EP2432489A2 (en) 2012-03-28
EP3175863A1 (en) 2017-06-07
WO2010135541A3 (en) 2011-01-20
USRE48267E1 (en) 2020-10-20
AU2010249802B2 (en) 2017-06-08
HUE057174T2 (hu) 2022-04-28
KR101831923B1 (ko) 2018-02-26
IL215287A (en) 2015-04-30
MX2011012277A (es) 2011-12-12
HRP20161739T1 (hr) 2017-03-10
BRPI1012783B1 (pt) 2021-09-21
JP5718909B2 (ja) 2015-05-13
USRE46707E1 (en) 2018-02-13
LUC00248I2 (da) 2025-03-04
HUE032582T2 (en) 2017-09-28
AU2010249802A1 (en) 2011-10-13
CN102481330A (zh) 2012-05-30
ES2608457T3 (es) 2017-04-11
EP2432489A4 (en) 2013-04-03
US20120316114A1 (en) 2012-12-13
EP4523749A2 (en) 2025-03-19
PL2432489T3 (pl) 2017-05-31
US8598121B2 (en) 2013-12-03
US20170051033A1 (en) 2017-02-23
KR102033680B1 (ko) 2019-10-18
PT3175863T (pt) 2022-01-20
PL3175863T3 (pl) 2022-03-21
FIC20220003I1 (fi) 2022-01-19
BRPI1012783A2 (pt) 2018-01-16
CA2758581A1 (en) 2010-11-25
US20160256553A1 (en) 2016-09-08
RU2573911C2 (ru) 2016-01-27
PT2432489T (pt) 2016-12-07
US20100297021A1 (en) 2010-11-25
KR20210027537A (ko) 2021-03-10
RU2011152007A (ru) 2013-06-27
CN102481330B (zh) 2014-12-10
NO2022003I1 (no) 2024-08-05
FR22C1004I2 (fr) 2023-01-13
HUS2200004I1 (hu) 2022-05-28
PE20120792A1 (es) 2012-07-27
CA2758581C (en) 2022-06-14
EP2432489B1 (en) 2016-10-05
EP4029512A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
DK3175863T3 (da) Varianter af c-type natriuretisk peptid
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
BRPI1009315A2 (pt) agentes anti-inflamatórios
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BRPI1008774A2 (pt) espiroamida substituída
DK2499139T3 (da) N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere
DK2417262T3 (da) Nanopartikelmedieret tilførsel af sekvensspecifikke nukleaser
EP2510088A4 (en) Oncolytic rhabdovirus
DK2260873T3 (da) Pcylering af proteiner
DK2459129T3 (da) Forbedringer af karstøtteanordninger
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
EP2392920A4 (en) CONNECTOR
BR112012005382A2 (pt) inibidores de jak
DK2411009T3 (da) Terapeutiske anvendelser af quinazolindionderivater
BRPI1008070A2 (pt) tricianoboratos
DK3128286T3 (da) Kombineret fyrværkeri
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
DK2453858T3 (da) Fremgangsmåde
DK2519512T3 (da) N1-acyl-5-fluorpyrimidinonderivater
EP2388861A4 (en) CONNECTOR
DOP2011000348A (es) Construcciones casb7439
DK2488157T3 (da) Forbedrede formuleringer
DK2501381T3 (da) Behandling af atrieflimmer
EP2507309A4 (en) NETWORKING RESOURCES